Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle Libre, Now Available To Medicare Patients - Jan 4, 2018
Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle Libre, Now Available To Medicare Patients
- CMS reimbursement provides opportunity for Medicare patients who meet eligibility criteria to access FreeStyle Libre System
- FreeStyle Libre System can replace traditional blood glucose monitoring, eliminating the need for routine fingersticks(1) or any user calibration
ABBOTT PARK, Ill., Jan. 4, 2018 / PRNewswire / --Abbott (NYSE: ABT) today announced that the FreeStyle Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). Coverage includes all Medicare patients with diabetes who use insulin and who meet the eligibility criteria2.
The factory-calibrated FreeStyle Libre system is the only CGM system recognized by Medicare that requires no user calibration whatsoever (either by fingerstick or manual data entry). The system also does not require the need for routine fingersticks1. The high accuracy of the FreeStyle Libre system allows for patients to dose insulin based on the results1.
"At Abbott, we are continuously challenging ourselves to ensure our innovative technology is accessible to the majority of people who need it," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "CMS's recognition of this revolutionary health technology, which removes the need for any user calibration, is ultimately going to empower Medicare beneficiaries with d Continue reading